DE69942280D1 - Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren - Google Patents

Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren

Info

Publication number
DE69942280D1
DE69942280D1 DE69942280T DE69942280T DE69942280D1 DE 69942280 D1 DE69942280 D1 DE 69942280D1 DE 69942280 T DE69942280 T DE 69942280T DE 69942280 T DE69942280 T DE 69942280T DE 69942280 D1 DE69942280 D1 DE 69942280D1
Authority
DE
Germany
Prior art keywords
alphavirus
vectors
packaging
nucleic acid
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69942280T
Other languages
English (en)
Inventor
John M Polo
Barbara A Belli
Thomas W Dubensky
Stephen F Hardy
Perri Silvia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Application granted granted Critical
Publication of DE69942280D1 publication Critical patent/DE69942280D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C12N2770/36152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Packages (AREA)
  • Wrappers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Laminated Bodies (AREA)
DE69942280T 1998-12-31 1999-12-30 Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren Expired - Lifetime DE69942280D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11473298P 1998-12-31 1998-12-31
PCT/US1999/031193 WO2000039318A1 (en) 1998-12-31 1999-12-30 Compositions and methods for packaging of alphavirus vectors

Publications (1)

Publication Number Publication Date
DE69942280D1 true DE69942280D1 (de) 2010-06-02

Family

ID=22357098

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69942280T Expired - Lifetime DE69942280D1 (de) 1998-12-31 1999-12-30 Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren

Country Status (7)

Country Link
US (1) US6242259B1 (de)
EP (1) EP1141361B1 (de)
AT (1) ATE465266T1 (de)
AU (1) AU2220800A (de)
CA (1) CA2359013C (de)
DE (1) DE69942280D1 (de)
WO (1) WO2000039318A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6844188B1 (en) 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6423544B1 (en) * 1998-12-31 2002-07-23 Chiron Corporation Compositions and methods for producing recombinant virions
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
EP1035205A1 (de) * 1999-03-08 2000-09-13 Stichting Dienst Landbouwkundig Onderzoek Sich nicht verbreitendes Pestivirus
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6982087B2 (en) * 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
WO2002062949A2 (en) 2000-10-20 2002-08-15 Canji, Inc Aptamer-mediated regulation of gene expression
CA2440890C (en) * 2001-03-27 2011-07-19 New York University Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
WO2002099035A2 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
WO2003029492A1 (en) * 2001-09-28 2003-04-10 Justin Gallivan Metabolic genes and related methods and compositions
EP1448588A4 (de) * 2001-10-23 2006-10-25 Psma Dev Company L L C Psma-antikörper und proteinmultimere
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
AU2003282538A1 (en) * 2002-10-10 2004-05-04 Oxford Biomedica (Uk) Limited Gene regulation with aptamer and modulator complexes for gene therapy
WO2004055167A2 (en) * 2002-12-13 2004-07-01 Alphavax, Inc. Alphavirus particles and methods for preparation
JP4991108B2 (ja) 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
EP1608762B1 (de) * 2003-03-20 2014-01-08 Alphavax, Inc. Verbesserte alphavirus replikons und helferkonstrukt
AU2004257214B2 (en) 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
CA2567254C (en) * 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
WO2006078294A2 (en) 2004-05-21 2006-07-27 Novartis Vaccines And Diagnostics Inc. Alphavirus vectors for respiratory pathogen vaccines
EP1773403B1 (de) * 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Auf alphavirus basierende adjuvanzien
US20060198854A1 (en) * 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
US8486420B2 (en) * 2005-02-15 2013-07-16 The University Of North Carolina At Chapel Hill Live virus vaccines
CN101218256B (zh) 2005-03-23 2017-04-19 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
EP2357000A1 (de) 2005-10-18 2011-08-17 Novartis Vaccines and Diagnostics, Inc. Mukosale und systemische Immunisierungen mit Alphavirus-Replikonpartikeln
WO2008033966A2 (en) * 2006-09-12 2008-03-20 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
NZ575476A (en) 2006-09-12 2012-07-27 Alphavax Inc Alphavirus replicon particles encoding il- 12 as immunological adjuvants
EP2099485B1 (de) * 2006-11-03 2018-03-21 AlphaVax, Inc. Zusammensetzungen aus alphaviren oder alphavirus replikon partikeln und dazugehörende methoden
CA2689588C (en) 2007-06-21 2016-08-23 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
WO2009058564A2 (en) 2007-11-01 2009-05-07 Maxygen, Inc. Immunosuppressive polypeptides and nucleic acids
US8680258B2 (en) 2008-12-01 2014-03-25 Alphavax, Inc. Use of microRNAs to control virus helper nucleic acids
AU2010234362B2 (en) 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
WO2012101509A2 (en) 2011-01-28 2012-08-02 Sanofi Pasteur Sa Immunological compositions against hiv
WO2014140938A2 (en) 2013-03-14 2014-09-18 Centre Hospitalier Universitaire Vaudois Immunological methods
CA3010974A1 (en) 2016-01-11 2017-07-20 Verndari, Inc. Microneedle compositions and methods of using same
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
ATE386811T1 (de) 1996-04-05 2008-03-15 Novartis Vaccines & Diagnostic Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen

Also Published As

Publication number Publication date
ATE465266T1 (de) 2010-05-15
CA2359013C (en) 2011-02-01
EP1141361B1 (de) 2010-04-21
EP1141361A1 (de) 2001-10-10
US6242259B1 (en) 2001-06-05
CA2359013A1 (en) 2000-07-06
WO2000039318A1 (en) 2000-07-06
AU2220800A (en) 2000-07-31

Similar Documents

Publication Publication Date Title
DE69942280D1 (de) Zusammensetzungen und verfahren zur verpackung von alpavirus-vektoren
DE69834908D1 (de) Verfahren zur erhöhung der expression von endogenen oder exogenen genprodukten in pflanzen
ATE443074T1 (de) Zubereitungen und methoden zur verwendung in rekombinatorischem klonen von nukleinsäuren
ZA967173B (en) Purified coprinus laccases and nucleic acids and encoding same
ATE447583T1 (de) Polypeptide und dafür kodierende nukleinsäure
DE69738521D1 (de) Alphaviren-vektors mit eine reduzierte inhibierung der synthese von zellmakromolekülen
CA2400295A1 (en) Modified factor viii
ATE478145T1 (de) Sekretierte und transmembran polypeptide und dafür kodierende nukleinsäuren
EP1460131A3 (de) Herstellung von rekombinanten Blutgerinnungsfaktoren in humanen Zellinien
EP0722461A4 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
ES2170622A1 (es) Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
MXPA01002592A (es) Polipeptidos de transmembrana y secretados y acidos nucleicos que codifican los mismos.
ATE384787T1 (de) Tripeptidyl-aminopeptidase
ATE454039T1 (de) Verfharen zur herstellung von herpes-simplex- virus-amplikons, die resultierenden amplikons und ihre verwendung
CA2390049A1 (en) Control of post-transcriptional gene silencing in plants
ATE288488T1 (de) Zusammensetzungen und verfahren zur eliminierung unerwünschter zellen
WO2000044898A3 (en) Novel agouti and agouti-related peptide analogs
ATE162853T1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
ATE318920T1 (de) Promotoren zur genexpression in karyopsen von pflanzen
BR9611851A (pt) Molécula de ácido nucléico isolada e purificada, vetor de experessão recombinatória, célula hospedeira contendo um vetor de expressão recombina tório, proteìnas tbpa e tbpb isolada e purificadas, método para preparar uma protéina tbpa e tbpb, anti-corpo policlÈnico ou monoclÈnico, e vacinas assim obtidas
ATE547427T1 (de) Verfahren zur rekombinanten herstellung von ribonukleoproteinen
DK0870050T3 (da) Virus, der udtrykker et toksisk protein, og producercellelinier
WO2000026340A3 (en) Novel nucleic acid molecules encoding opioid growth factor receptors
DK1277833T3 (da) Gener, der opformeres i tumorer, samt relaterede materialer og metoder
FR2859221B1 (fr) Vecteur de co-expression de domaines membranaires de proteines d'enveloppe d'un virus et utilisations

Legal Events

Date Code Title Description
8364 No opposition during term of opposition